Since the inaugural workshop “Understanding High-Dose, Ultra-High Dose Rate and Spatially Fractionated Radiotherapy.” hosted by the NCI and sponsored by the Radiosurgery Society (RSS), growing collaborations and investigations have ensued among experts, practitioners, and researchers. The RSS GRID, Lattice, Microbeam & FLASH (GLMF) Working Groups were formed as a framework for these efforts and have focused on advancing the understanding of the biology, technical/physical parameters, trial design, and clinical practice of these new radiation therapy modalities.

This article reviews toxicity outcomes for a series of patients treated with stereotactic radiosurgery for trigeminal neuralgia, focusing on dose to the brainstem, trigeminal nerve, and Meckel’s cave as possible explanatory variables for the development of the most common posttreatment neuropathy, facial numbness.

Data informing the safety, efficacy, treatment logistics, and dosimetry of stereotactic body radiation therapy (SBRT) for lung tumors has primarily been derived from patients with favorably located solitary tumors. SBRT is now considered a standard-of-care treatment for inoperable early-stage non-small cell lung cancer and lung metastases, and therefore extrapolation beyond this limited foundational patient population remains an active source of interest.

The time that elapses between a patient’s ablative tumor resection and indicated adjuvant radiation has a significant impact on an individual’s local control and survival, and its optimization is in the best interest of the patient. Furthermore, it is a recognized treatment related quality metric which can have bearing on future provider compensation. Despite these important driving considerations, compliance rates with established goals are low, recently measured below 50%. Making meaningful and lasting improvements in this requires a systems based approach.